Route 92 Medical

Route 92 Medical is a medical device company that develops catheter-based technologies for the treatment of acute ischemic stroke and other neurovascular conditions. Founded by physicians, the company combines engineering and product design with collaboration with neurovascular clinicians worldwide, with a stated focus on improving outcomes for patients undergoing neurovascular intervention. Its work spans catheter-based medical device engineering, direct aspiration and reperfusion technology, and neurointervention.

The company's product portfolio includes the FreeClimb Catheter Systems and the HiPoint Reperfusion System, which features the Monopoint Approach; both are designed to help clinicians quickly restore blood flow to a patient's brain following acute ischemic stroke. The HiPoint 88 Reperfusion System is described as a super-bore catheter for direct aspiration of large vessel occlusions in the neurovasculature, and is claimed to be the first and only FDA-cleared super-bore 0.088-inch catheter for that purpose.

Route 92 Medical operates in the medical devices, stroke care and interventional neuroradiology sectors, with a presence in the United States and collaboration with clinicians globally. The scale of the field it addresses includes roughly 16 million strokes worldwide each year, around 6 million stroke deaths, and more than 800,000 acute ischemic stroke patients a year in the United States, where the annual healthcare cost of the condition is put at $104 billion.